{"id":2970,"date":"2021-02-17T16:05:00","date_gmt":"2021-02-17T09:05:00","guid":{"rendered":"https:\/\/infosite.hitap.net\/challenges-in-ensuring-global-access-to-covid-19-vaccines-production-affordability-allocation-and-deployment\/"},"modified":"2022-03-01T14:24:02","modified_gmt":"2022-03-01T07:24:02","slug":"challenges-in-ensuring-global-access-to-covid-19-vaccines-production-affordability-allocation-and-deployment","status":"publish","type":"post","link":"https:\/\/infosite.hitap.net\/en\/challenges-in-ensuring-global-access-to-covid-19-vaccines-production-affordability-allocation-and-deployment\/","title":{"rendered":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2970\" class=\"elementor elementor-2970 elementor-2740\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6ab8bbd1 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6ab8bbd1\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-592fc7f5\" data-id=\"592fc7f5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3a77e75a elementor-widget elementor-widget-text-editor\" data-id=\"3a77e75a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.10.0 - 09-01-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#818a91;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#818a91;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><div class=\"post-views content-post post-2970 entry-meta\">\r\n\t\t\t\t<span class=\"post-views-icon dashicons dashicons-welcome-view-site\"><\/span> <span class=\"post-views-label\">\u0e08\u0e33\u0e19\u0e27\u0e19\u0e1c\u0e39\u0e49\u0e40\u0e02\u0e49\u0e32\u0e0a\u0e21:<\/span> <span class=\"post-views-count\">1,388<\/span>\r\n\t\t\t<\/div><\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1be6490e elementor-widget elementor-widget-text-editor\" data-id=\"1be6490e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<h2 class=\"section-title u-h3 u-margin-l-top u-margin-xs-bottom\">Summary<\/h2>\n<div id=\"ceabs10\">\n<p id=\"spara110\">The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26\u2008758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).<\/p>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51fb1e63 elementor-align-justify elementor-widget elementor-widget-button\" data-id=\"51fb1e63\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t<a href=\"https:\/\/www.hitap.net\/wp-content\/uploads\/2021\/02\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment.pdf\" class=\"elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-text\">\u0e14\u0e32\u0e27\u0e19\u0e4c\u0e42\u0e2b\u0e25\u0e14\u0e40\u0e2d\u0e01\u0e2a\u0e32\u0e23<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-52a88283 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"52a88283\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-62226725\" data-id=\"62226725\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6a155fd1 elementor-widget elementor-widget-image\" data-id=\"6a155fd1\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.10.0 - 09-01-2023 *\/\n.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=\".svg\"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}<\/style>\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.hitap.net\/wp-content\/uploads\/2021\/02\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment.pdf\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1906\" height=\"2560\" src=\"https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-scaled.jpg\" class=\"attachment-full size-full wp-image-2972\" alt=\"\" srcset=\"https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-scaled.jpg 1906w, https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-223x300.jpg 223w, https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-763x1024.jpg 763w, https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-768x1031.jpg 768w, https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-1144x1536.jpg 1144w, https:\/\/infosite.hitap.net\/wp-content\/uploads\/2021\/08\/Challenges-in-ensuring-global-access-to-COVID-19-vaccines_production-affordability-allocation-and-deployment_001-1525x2048.jpg 1525w\" sizes=\"auto, (max-width: 1906px) 100vw, 1906px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Summary The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[72],"tags":[],"class_list":["post-2970","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-international-publications-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/posts\/2970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/comments?post=2970"}],"version-history":[{"count":3,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/posts\/2970\/revisions"}],"predecessor-version":[{"id":3722,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/posts\/2970\/revisions\/3722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/media\/2974"}],"wp:attachment":[{"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/media?parent=2970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/categories?post=2970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infosite.hitap.net\/en\/wp-json\/wp\/v2\/tags?post=2970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}